539 results on '"Gale AN"'
Search Results
2. Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy
3. Glucose uptake capacity of leukaemia cells in vitro correlates with response to induction therapy in acute myeloid leukaemia
4. A modest proposal to the transplant publik to prevent harm to people with acute myeloid leukaemia in 1st complete remission cured by chemotherapy
5. Challenges in analyzing clinical trials testing Bruton tyrosine-kinase-inhibitors in chronic lymphocytic leukaemia
6. Is there really an accelerated phase of chronic myeloid leukaemia?
7. Predicting survival in patients with myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis
8. Measurable residual disease (MRD)-testing in haematological and solid cancers
9. Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients.
10. Prognostic impact of CEBPA mutational subgroups in adult AML
11. Radiation exposure and space exploration
12. Measurable residual disease in haematological and solid cancers
13. Prof. Constance Jean Eaves: Doyenne of Stem Cells. May 22, 1944 – March 7, 2024
14. What do atomic bomb survivors teach us about therapy-free remission in people with chronic myeloid leukaemia?
15. Mutations in DEAD/H-box helicase 11 correlate with increased relapse risk in adults with acute myeloid leukaemia with normal cytogenetics
16. Correction: To Mars and beyond. Space exploration and space medicine in Leukemia
17. To Mars and beyond. Space exploration and space medicine in Leukemia
18. Have we been qualifying measurable residual disease correctly?
19. Are haematopoietic stem cell transplants stem cell transplants, is there a threshold dose of CD34-positive cells and how many are needed for rapid posttransplant granulocyte recovery?
20. How should we interpret conclusions of TKI-stopping studies
21. Nuclear war and physicians’ social responsibility
22. Glucose partitioning in the bone marrow micro-environment in acute myeloid leukaemia
23. Validation of the imatinib-therapy failure model
24. External validation of the predictive scoring systems for molecular responses in chronic myeloid leukaemia receiving initial imatinib-therapy
25. Why are haematopoietic stem cells in the bone marrow: ontology recapitulates phylogeny
26. Myelofibrosis-type megakaryocyte dysplasia (MTMD) as a distinct category of BCR::ABL-negative myeloproliferative neoplasms. Challenges and perspectives
27. Correction: Are haematopoietic stem cell transplants stem cell transplants, is there a threshold dose of CD34-positive cells and how many are needed for rapid posttransplant granulocyte recovery?
28. Comparison of the revised 4th (2016) and 5th (2022) editions of the World Health Organization classification of myelodysplastic neoplasms
29. A prognostic survival nomogram for persons with extra-nodal natural killer-/T-cell lymphoma
30. Is unmeasurable residual disease (uMRD) the best surrogate endpoint for clinical trials, regulatory approvals and therapy decisions in chronic lymphocytic leukaemia (CLL)?
31. Sensitive quantitative IgD assay increases progression-free survival prediction accuracy in IgD plasma cell myeloma
32. Predictive scoring systems for molecular responses in persons with chronic phase chronic myeloid leukemia receiving initial imatinib therapy
33. Co-variates associated with outcomes of tyrosine kinase-inhibitor therapy in persons with chronic myeloid leukaemia initially presenting in accelerated phase
34. Changing causes of death in persons with haematological cancers 1975–2016
35. Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia
36. A predictive scoring system for therapy-failure in persons with chronic myeloid leukemia receiving initial imatinib therapy
37. Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors?
38. Prognostic value of Oncogenetic mutations in pediatric T Acute Lymphoblastic Leukemia: a comparison of UKALL2003 and FRALLE2000T protocols
39. Measurable residual disease testing in chronic lymphocytic leukaemia: hype, hope neither or both?
40. Improving prediction accuracy in acute myeloid leukaemia: micro-environment, immune and metabolic models
41. A prognostic survival model based on metabolism-related gene expression in plasma cell myeloma
42. HUGO Gene Nomenclature Committee (HGNC) recommendations for the designation of gene fusions
43. Correction to: Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113AML patients
44. A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence.
45. RBC distribution width predicts thrombosis risk in polycythemia vera
46. NK-/T-cell lymphomas
47. JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis
48. High incidence of MYD88 and KMT2D mutations in Chinese with chronic lymphocytic leukemia
49. Why chronic myeloid leukaemia cannot be cured by tyrosine kinase-inhibitors
50. Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.